Research Article
Inter- Not Intraindividual Differences in sTWEAK Levels Predict Functional Deterioration and Mortality in Patients with Dilated Cardiomyopathy
Table 1
Characteristics of the study cohort with dilated cardiomyopathy (
).
| | Age (years) | 55 (43–64) | | Gender (m/f) | 56/22 | | Ejection fraction in % | 29.5 (20–45) | | Left ventricular end-diastolic diameter (in mm) | 60 (52–66) | | 6-minute walk test (distance in m) | 503 (417–596) | | Peak oxygen consumption (L/min/kg) | 17.6 (14.5–23) | | NYHA class | | | Class I | 36 (46.1%) | | Class II | 37 (47.4%) | | Class III | 5 (6.4%) | | Class IV | 0 (0%) | | Medication | | | β-Blockers | 74 (94.9%) | | ACEI/AT antagonists | 77 (98.7%) | | Aldosterone antagonists | 41 (52.6%) | | Diuretics | 53 (67.9%) | | Glycosides | 23 (29.5%) | | Diabetes | 6 (7.7%) | | Creatinine (mg/dL) | 0.93 (0.8–1.2) | | sTWEAK in pg/mL | 603 (423–839) | | sCD163 in ng/mL | 2554 (1990–3479) | | NT-proBNP in ng/L | 482 (211–1505) | | Death/heart transplantation on 4-year follow-up | 4/1 | | Functional deterioration (≥1 NYHA class) | 41 (52.6%) | | Functional deterioration (≥2 NYHA classes) | 11 (14.1%) |
|
|
Values given as median (IR), number, or number (%).
|
